Neutron Therapeutics develops a comprehensive solution for Boron Neutron Capture Therapy (BNCT), centered on its nuBeam® neutron source and associated systems. The company applies high‑power proton accelerator technology to enable practical, in‑hospital neutron beam generation for BNCT. Neutron is partnering with Cosylab to incorporate Cosylab’s OncologyOne radiation therapy software into nuBeam® systems and to bundle the solutions for hospitals worldwide. The strategic collaboration includes an investment element valued at up to $25M, with Cosylab receiving equity in exchange for cash, software development expertise and other in‑kind contributions. Neutron was founded in 2015 and is headquartered just outside of Boston, MA. The nuBeam® neutron source is not approved for commercial or clinical use by the FDA, PMDA, EMA or other regulatory body.

Total raised

$25M

Funding rounds

1

Latest round

Equity

Latest activity

Jan 2022